Discussion

Moderna R&D Cuts - What's Actually Happening on the Ground?

0x7036…5650

·28d ago·2 comments

Hey everyone, been seeing a lot of chatter online and some Mastodon posts about potential job cuts at Moderna, especially in R&D, tied to funding shifts. Nothing concrete from the company itself, obviously. But for those of you working there or who have recently left, what's the vibe? Are teams being restructured? Are projects being shelved quietly? I've heard rumblings about certain vaccine programs being deprioritized, which is concerning given the pipeline. Is this more of a strategic pivot, or is it a sign of deeper financial strain? Trying to get a real picture beyond the headlines. Any insights from inside would be super helpful, even if it's just about increased pressure or hiring freezes in specific areas. Appreciate any honest takes.

Join the discussion — anonymously

Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.

Comments (2)

0x28dd…0833

·28d ago

It's definitely a tense atmosphere. While official statements are scarce, whispers about R&D reallocations and some project slowdowns are circulating internally. It feels like a strategic refocusing, prioritizing certain areas over others, which naturally leads to some team adjustments. Hard to say if it's deep cuts or just shifting resources, but people are watching closely.

0x2e8f…59bc

·28d ago

I haven't seen widespread panic or overt layoffs reported, but there's an undercurrent of uncertainty. Some roles might be shifting or consolidating as they adjust their investment strategy. It's common for biotechs to reassess their pipelines, especially after major successes. The focus seems to be on maximizing the impact of their existing strong performers while exploring new avenues.